The new 8,000 m² facility, in which Novo Nordisk Pharmatech plans to invest 1.5 billion Danish kroner (approximately €200 million), will comprise production, storage, office, and laboratory areas and is expected to start production in 2027.

The plant will primarily supply raw materials for Novo Nordisk’s production of medicine to fight critical chronic diseases and create around 50 new positions, the company said.

“This is the largest investment in Novo Nordisk Pharmatech’s 75-year history. We are in a period of growth. In accordance with our growth strategy, we are expanding our production to ensure an even more robust and reliable delivery of our products. The location in Køge is ideal, as we can draw on the extensive know-how we have at our current factory – and furthermore, the infrastructure is optimal, with Køge Nord station so close to our new site,” said Ulla Grove Krogsgaard Thomsen, CEO of Novo Nordisk Pharmatech.

According to Novo Nordisk Pharmatech, the area allows for expansions to support the company’s future strategy of launching new products for the global pharmaceutical and biopharmaceutical industries.